Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($1.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3,520.00) by $3,518.28, FiscalAI reports.
Bluejay Diagnostics Stock Down 6.8%
Shares of NASDAQ BJDX traded down $0.19 during trading hours on Thursday, hitting $2.61. 17,710 shares of the stock were exchanged, compared to its average volume of 538,357. The company has a market cap of $2.92 million, a PE ratio of -0.09 and a beta of 0.92. The firm has a fifty day moving average price of $3.10 and a 200-day moving average price of $7.05. Bluejay Diagnostics has a 12 month low of $1.84 and a 12 month high of $28.00.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on BJDX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Monday, September 21st. Wall Street Zen cut Bluejay Diagnostics from a “hold” rating to a “sell” rating in a research note on Monday, September 14th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Bluejay Diagnostics currently has a consensus rating of “Sell”.
About Bluejay Diagnostics
Bluejay Diagnostics, Inc. is a medical technology company focused on developing rapid, point-of-care diagnostic testing solutions. The company’s technology is designed to provide healthcare professionals with timely information from blood samples, supporting clinical decision-making in settings where conventional laboratory testing may take longer. Its primary product is the Symphony system, a diagnostic platform consisting of an analyzer and disposable test cartridges. The platform is intended to measure biomarkers in whole blood and is being developed for applications including the assessment and management of serious medical conditions such as sepsis and other critical-care situations.
Recommended Stories
- Five stocks we like better than Bluejay Diagnostics
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
